A recent small-scale clinical trial showed that Atractylodes lancea (AL) could help slow down tumor growth and reduce death rates in people with advanced liver cancer. This study looked into figuring out the best dose of AL to use in future trials. The original trial found that doses between 1, 000 and 2, 000 mg were effective. The goal here was to build on that, making sure the next phase of trials has the right dose from the start.

Researchers used a special type of model that considers how the drug affects the body over time and across different people. This is important because everyone's body is unique, and what works for one person might not work for another. By understanding these differences, they can make a more informed decision about the best dose to use.

The study also considered how much of the drug actually gets into the body and how it's broken down. This is called pharmacokinetics. They also looked at how the drug affects the body, which is called pharmacodynamics. Both of these are crucial for understanding how well a drug works and how safe it is.

The results showed that a dose of 1, 500 mg of AL seems to be a good balance between being effective and safe. This means that in the future trials, they'll start with this dose and see how well it works. It's important to note that this is still just a prediction and the real test will be in the next phase of trials.

CLINICAL STUDY

Exploring the Best Dose of Atractylodes lancea for Advanced Liver Cancer

Continue reading...